Prenatal Exposure to Phthalates Significantly Associated With Elevated Rate of Language Delay in Children in Sweden and the U.S.
In the first study of its kind, researchers from the Icahn School of Medicine at Mount Sinai and Karlstad University in Sweden have found an elevated rate of language delay in children at 30 months old who were born to mothers exposed to phthalates, synthetic chemicals found in common household items and personal care products.
The study, the first to examine early language development in relation to first-trimester phthalate exposure as measured in urine levels, was published in JAMA Pediatrics.
The Swedish Environmental Longitudinal, Mother and Child, Asthma and Allergy study (SELMA) in Sweden and The Infant Development and the Environment Study (TIDES) in the United States provided data for the research.
Information was gathered from 963 pregnant women and their children from the Swedish study and 370 women and their children from the U.S. study. Parents were asked how many words their children understood at 30 months in SELMA and at 37 months in TIDES. Ten percent of children in both studies experienced language delay, with higher rates in boys than in girls. Children who understood fewer than 50 words were classified with language delay. Phthalate levels were measured in urine samples obtained from the women at median 10th week of pregnancy in both cohorts. The risk for language delay was higher by up to 30 percent in children whose mothers had doubled exposure levels of two chemicals: dibutyl phthalate (DBP) and butyl benzyl phthalate (BBP), both of which are commonly found in household products including older vinyl flooring, cosmetics, and plastic toys.
Before statistical adjustment results were statistically significant in both studies. After adjusting for potential confounders, results were significant in the Swedish study, but not in the U.S. study, likely due to its smaller sample size
“Given the prevalence of prenatal exposure to these chemicals and the importance of language development, pregnant women should try to reduce their exposure to phthalates by choosing scent-free personal care products and phthalate-free nail polish,” said the study’s senior author, Shanna Swan, PhD, Professor of Environmental and Public Health at the Icahn School of Medicine at Mount Sinai. “However, these phthalates are hidden in many household products like older vinyl floor covering and upholstery and are hard to avoid since there is no labeling of ingredients in these products.”
“We were surprised by how similar the results were between the two very different populations in Sweden and the U.S.” said principal investigator Carl-Gustaf Bornehag, PhD, Professor, Karlstad University, Sweden and adjunct professor at Icahn School of Medicine at Mount Sinai. “It’s important for us to look at language development because it has shown to be predictive of other neurodevelopmental problems in children.”
The SELMA and TIDES studies will follow the children and re-examine language development at seven and six years respectively.
Other researchers from Mount Sinai include Avraham Reichenberg, PhD, Professor of Psychiatry, and Sarah Evans, PhD, Assistant Professor, Environmental Medicine and Public Health. Other institutions involved in this study include Karlstad University in Sweden, Institute of the Ruhr-University in Germany, and Lund University in Sweden, and the University of Rochester School of Medicine, University of Minnesota, University of Washington and University of California-Berkeley.
This study was supported by grants from the National Institute of Environmental Health Sciences, the Swedish Research Council Formas and from the County Council of Varmland, Sweden.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.